Tesamorelin
GHRH analog studied for visceral adiposity research.
Evidence Level
Strong
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
GHRH analog studied for visceral adiposity research.
/ 02
Mechanism of Action
Studied for GHRH receptor activation and pulsatile GH release.
/ 03
Research Applications
Visceral fat, IGF-1 pathway research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH). Research describes pituitary-level stimulation of GH secretion, leading to downstream IGF-1 axis activation and reported effects on visceral adipose tissue in studied populations.
/ 08
Pathway Role
Operates within the GH/IGF-1 axis at the hypothalamic-pituitary signaling layer, upstream of systemic IGF-1 effects.
/ 09
Biological Targets
/ 10
Research Applications
- HIV-associated lipodystrophy (approved indication)
- Visceral adipose tissue research
- GH axis stimulation studies
/ 11
Evidence Summary
Strong evidence within its approved clinical context. Outside that population, generalization is not supported.
Evidence Level Rationale
Rated strong for its approved context due to well-controlled clinical trials, but limited outside that scope.
/ 12
Research Observation Timeline
Early Signal Window
GH/IGF-1 axis biomarker shifts within weeks
Primary Study Window
Clinical studies measured visceral adipose tissue changes at 26 weeks, with extension data to 52 weeks
Endpoint Type
Imaging and biomarker endpoints
Evidence Strength
Strong within approved context
/ 13
Safety & Unknowns
Adverse event profile in trials includes effects related to GH/IGF-1 axis activation. FDA labeling explicitly states it is not indicated for weight-loss management.
/ 14
Research Limitations
Outcome data outside HIV-associated lipodystrophy is limited. Off-label generalization is not supported by trial evidence.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Strong
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
AOD-9604
Fragment of hGH (176-191) studied in lipid metabolism research.
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.